Successful Dosing of Final Patient in ACHIEVE Safety Cohort of TCB008 Trial Announced February 8, 2023
Kite And Arcellx Close Agreement To Co-Develop And Co-Commercialize Late-Stage Clinical CART-DdBCMA In Multiple Myeloma February 8, 2023
CARsgen Announces Collaboration Agreement to Evaluate AB011 in Combination with Atezolizumab to Treat Gastric Cancer February 8, 2023
Hillstream BioPharma Signs an Exclusive Option Agreement to Advance Next-Gen Anti-MUC1-C Agents for Drug-Resistant Cancers February 8, 2023
Ratio Therapeutics Announces $20M Series A Financing to Advance Targeted Radiotherapies for Cancer Treatment February 8, 2023
Guardant Health and AnHeart Therapeutics to Develop Guardant360 CDx and Guardant360 TissueNext™ as Companion Diagnostics for Taletrectinib in ROS1-Positive mNSCLC February 8, 2023
TROPION-Lung07 Ph 3 Trial Initiated to Evaluate Datopotamab Deruxtecan in Combination with Pembrolizumab in 1L mNSCLC Patients February 8, 2023
First Patient Dosed in NMIBC Substudy of the LUMINOS-103 Basket Trial Evaluating Lerapolturev Monotherapy February 8, 2023
Expansion Portion of UPGRADE-A Combination Clinical Trial in Platinum-Sensitive Ovarian Cancer Initiated February 8, 2023
Avutometinib + Defactinib Combination Advancing in Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) Based on Positive Data from Planned Interim Analysis of Part A of RAMP 201 Trial February 8, 2023
NRG-GY018 Study Demonstrates Significantly Improved PFS Outcomes for Women with Endometrial Cancer with the Addition of Pembrolizumab to Chemotherapy February 8, 2023
KEYTRUDA + Chemo Met Primary Endpoint of PFS as First-Line Therapy for Advanced or Recurrent Endometrial Carcinoma February 8, 2023
FDA Approves Jaypirca™ (pirtobrutinib) for Adult Patients with R/R Mantle Cell Lymphoma After at Least Two Lines of Systemic Therapy, Including a BTKi February 8, 2023
FDA approves Orserdu (elacestrant) for endocrine therapy-treated postmenopausal women or adult men with ER+ve, HER2-neg, ESR1-mutated advanced or metastatic breast cancer February 8, 2023
